Extracellular Vesicles in Hepatobiliary Malignancies.

IF 5.9 2区医学 Q1 IMMUNOLOGY Frontiers in Immunology Pub Date : 2018-10-12 eCollection Date: 2018-01-01 DOI:10.3389/fimmu.2018.02270

Ainhoa Lapitz, Ander Arbelaiz, Paula Olaizola, Aitziber Aranburu, Luis Bujanda, Maria J Perugorria, Jesus M Banales

{"title":"Extracellular Vesicles in Hepatobiliary Malignancies.","authors":"Ainhoa Lapitz, Ander Arbelaiz, Paula Olaizola, Aitziber Aranburu, Luis Bujanda, Maria J Perugorria, Jesus M Banales","doi":"10.3389/fimmu.2018.02270","DOIUrl":null,"url":null,"abstract":"<p><p>Primary hepatobiliary malignancies include a heterogeneous group of cancers with dismal prognosis, among which hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and hepatoblastoma (HB) stand out. These tumors mainly arise from the malignant transformation of hepatocytes, cholangiocytes (bile duct epithelial cells) or hepatoblasts (embryonic liver progenitor cells), respectively. Early diagnosis, prognosis prediction and effective therapies are still a utopia for these diseases. Extracellular vesicles (EVs) are small membrane-enclosed spheres secreted by cells and present in biological fluids. They contain multiple types of biomolecules, such as proteins, RNA, DNA, metabolites and lipids, which make them a potential source of biomarkers as well as regulators of human pathobiology. In this review, the role of EVs in the pathogenesis of hepatobiliary cancers and their potential usefulness as disease biomarkers are highlighted. Moreover, the therapeutic value of EV regulation is discussed and future directions on basic and clinical research are indicated.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":" ","pages":"2270"},"PeriodicalIF":5.9000,"publicationDate":"2018-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3389/fimmu.2018.02270","citationCount":"25","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fimmu.2018.02270","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 25

Abstract

Primary hepatobiliary malignancies include a heterogeneous group of cancers with dismal prognosis, among which hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and hepatoblastoma (HB) stand out. These tumors mainly arise from the malignant transformation of hepatocytes, cholangiocytes (bile duct epithelial cells) or hepatoblasts (embryonic liver progenitor cells), respectively. Early diagnosis, prognosis prediction and effective therapies are still a utopia for these diseases. Extracellular vesicles (EVs) are small membrane-enclosed spheres secreted by cells and present in biological fluids. They contain multiple types of biomolecules, such as proteins, RNA, DNA, metabolites and lipids, which make them a potential source of biomarkers as well as regulators of human pathobiology. In this review, the role of EVs in the pathogenesis of hepatobiliary cancers and their potential usefulness as disease biomarkers are highlighted. Moreover, the therapeutic value of EV regulation is discussed and future directions on basic and clinical research are indicated.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肝胆恶性肿瘤的细胞外囊泡。

原发性肝胆恶性肿瘤包括一组预后不佳的异质性癌症，其中肝细胞癌(HCC)、胆管癌(CCA)和肝母细胞瘤(HB)尤为突出。这些肿瘤主要分别由肝细胞、胆管细胞(胆管上皮细胞)和肝母细胞(胚胎肝祖细胞)的恶性转化而产生。早期诊断、预后预测和有效治疗仍然是这些疾病的理想。细胞外囊泡(EVs)是由细胞分泌的小的膜封闭球体，存在于生物液体中。它们含有多种类型的生物分子，如蛋白质、RNA、DNA、代谢物和脂质，这使它们成为生物标志物和人类病理生物学调节剂的潜在来源。在这篇综述中，强调了ev在肝胆癌发病机制中的作用及其作为疾病生物标志物的潜在用途。此外，本文还讨论了EV调节的治疗价值，并指出了今后的基础和临床研究方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Frontiers in Immunology IMMUNOLOGY-

CiteScore

9.80

自引率

11.00%

发文量

7153

审稿时长

14 weeks

期刊介绍： Frontiers in Immunology is a leading journal in its field, publishing rigorously peer-reviewed research across basic, translational and clinical immunology. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. Frontiers in Immunology is the official Journal of the International Union of Immunological Societies (IUIS). Encompassing the entire field of Immunology, this journal welcomes papers that investigate basic mechanisms of immune system development and function, with a particular emphasis given to the description of the clinical and immunological phenotype of human immune disorders, and on the definition of their molecular basis.